Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

Pfizer sues Texas agency over leak of drug prices

November 21, 2016 Medical Communications, Sales and Marketing Drug pricing, Pfizer, US, texas

Pfizer has sued Texas’ Health and Human Services Commission, after it claimed the agency violated state and federal law by …
News

China conducts first gene-editing human trial

November 21, 2016 Research and Development, Sales and Marketing China, DNA, cas9, crispr

China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject, suffering from metastatic lung cancer. This …
News

GSK 18 months ahead of the game with three-drug inhaler

November 21, 2016 Medical Communications, Sales and Marketing GSK, Innoviva, chronic obstructive pulmonary disease

GlaxoSmithKline, alongside its partner Innoviva, have filed a regulatory submission with the FDA for its treatment for chronic obstructive pulmonary …
News

Teva’s drug to replace chemotherapy in acute leukaemia

November 21, 2016 Medical Communications, Sales and Marketing Teva, chemotherapy, first line, first-line, leukaemia

Teva Pharmaceutical announced that their drug Trisenox has been given approval from the European Commission to become the first line …
News

Novartis in $665 million deal for Selexys

November 21, 2016 Sales and Marketing Novartis, SelG1, selexys

Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …
News

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
News

Former Valeant executive and Philidor CEO charged with fraud

November 18, 2016 Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud

Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …
News

NICE thumbs up for BMS leukaemia treatment

November 18, 2016 Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia

Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
News

New healthcare app aims to improve patient adherence

November 17, 2016 Medical Communications, Sales and Marketing Echo, app, patient adherence, smartphone

The newly released app, named Echo, was developed by former Apple executive Dr Sai Lakshmi and former LloydsPharmacy executive Stephen …
News

Japan to slash Opdivo costs by 50%

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo

Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
News

Amgen boosted in race to market for migraine drug

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
News

NICE rules Shire’s Onivyde not cost effective

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
News

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
News

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
News

Real world evidence: a reality check for pharma?

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence

Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Feature
The Gateway to Local Adoption Series

Latest content

From lab breakthrough to NHS treatment: Getting innovative therapies to patients

September 5, 2026

Five Facts about NHS and primary care

September 5, 2026

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.

September 5, 2026

AI in pharma: From lab development to patient impact

September 5, 2026

Back to basics: X-ray inspection in pharmaceutical and medical device production

September 5, 2026